Armata Pharmaceuticals, Inc. — Director's Dealing 2014

Feb 18, 2014

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AmpliPhi Biosciences Corp (APHB)
CIK: 0000921114
Period of Report: 2014-02-18

Reporting Person: Young Philip J (Director, President and CEO)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$0.20	2022-10-23	Common Stock (8400000)		Direct
Stock Option (right to buy)	$0.16	2023-06-25	Common Stock (11600000)		Direct

Footnotes

F1: The shares underlying this option shall vest and become exercisable in accordance with the following schedule: 6.25% of the total number of shares shall vest and become exercisable on the third month anniversary of the date of grant and 6.25% of the total number of shares shall vest and become exercisable on the first business day of each three (3) month period thereafter.

F2: The shares underlying this option shall vest and become exercisable in accordance with the following schedule: 3,828,000 shares shall be vested on the date of grant, and the remaining shares shall vest monthly at the rate of 1/36 of the remaining shares per month on each monthly anniversary of the date of the grant.